Nicholas Wrigley


FDA approves niraparib/abiraterone tablet for BRCA-positive mCRPC

The approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.

Aaron Berger, MD


Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate Cancer

Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.

Brad Schwartz, DO, FACS


Fluoroscopic Imaging and Other Developments in Urology

The rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.

Victoria Troesch


Urologic research and COVID-19: Unmasking the silver lining

In this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.

Jonah Feldman


Worse rPFS, OS observed in patients with BRCA-mutated mCRPC vs non-BRCA

“These results further support the importance of screening for germline and somatic BRCA1/2 alterations to deliver more precise care for our patient," says David Olmos, MD, PhD.

Ken Nuss


Money Matters: Expert on why annuities are the “Swiss Army knife” of personal finance

Social Security benefits aren’t sufficient to fund retirement for most people. And given the aging of the population and projected trust-fund shortfall, they may be less generous in the future.

Sara Karlovitch


Perioperative cabozantinib shows promise in metastatic kidney cancer

Perioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.

Nour Abdallah, MD


Race-based adjustment of eGFR: Current opinions and impact on urologic oncology

“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.

Deborah M. Shlian, MD, MBA


Despite overall gains, leadership and payment gaps remain for women in medicine

"The good news is that women have been entering medicine in increasing numbers for more than three decades. The not-so-good news is that women are still underrepresented and underutilized in positions of power," writes Deborah M. Shlian, MD, MBA.

Armine K. Smith, MD


EP. 4B: Educating Patients on Their Treatment Options for LG UTUC

In this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.

Chris Mazzolini


Expert insight on ransomware: Is your practice prepared?

Ransomware has never been a more serious threat for health care organizations, even small medical practices.

Richard David, MD, FACS


Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate Cancer

Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.

Meredith E. Donahue, APRN-BC


How APPs can be involved with genitourinary cancer care

A nurse practitioner discusses how she supports multiple providers in a large academic practice.

Edward M. Schaeffer, MD, PhD


Moving transperineal prostate biopsy into the clinic

Learning curve for technique is short, but capital expenditures are required.

Russell Libby, MD


Expert Opinion: We cannot continue to ignore the problem of physician mental distress

"We need health systems, state medical boards and physician employment settings to commit to prioritizing physician wellbeing and provide the reassurances and resources that encourage physicians in need to seek help," writes Russell Libby, MD.

Todd Shryock


Survey shows significant impact of billing process on patients’ choice of provider

Although traditional payment and communication methods remain relevant, the survey highlights a paradigm shift in patients' billing expectations overall.

Julie N. Graff, MD


Novel dual agents for advanced prostate cancer

A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.

Yale School of Medicine


Study shows promise of immunotherapy treatment for penile cancer

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

Munir Ghesani, MD


Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence 

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

Katie Robinson


MRI-based screening emerging as viable alternative to PSA testing

“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.

David Friede


Is greater patient control of their personal health records a plus for physicians?

The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.

Moffitt Cancer Center


Moffitt study shows genomic testing can identify African American prostate cancer patients with high-risk disease

Moffitt Cancer Center conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer

Boris Gershman, MD


Emulating target trials using observational evidence to inform clinical decision-making

"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.

Ron Southwick


Survey shows high mistreatment rates among women, minority groups in academic medicine

The findings of harassment and inappropriate behavior come at a time when there is widespread agreement among health care leaders about the need for a more diverse physician workforce.

Rizwan Nurani, MD


Urology Perspective on Radiation Toxicity in Prostate Cancer

Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.

Lucienne Marie Ide, MD, PhD


Can remote patient monitoring help combat the staffing shortage?

"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.

Jason Hafron, MD


Unmet Needs and Investigational Therapies in mCSPC

Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.

Scott Webster, MD


PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Evan R. Goldfischer, MD, MBA, FACS


Chronic care management in the urologic oncology setting

CCM programs can engage multiple providers to care for patients while reducing in-person visits.

© 2023 MJH Life Sciences

All rights reserved.